Geographic Atrophy clinical trials at UC Health
3 in progress, 1 open to new patients
-
Metformin vs. no treatment in the progression of geographic atrophy (GA), a type of age-related macular eye degeneration (AMD)
“Can Metformin, used to treat Diabetes, slow the progression of geographic atrophy in patients with age-related macular eye degeneration?”
open to eligible people ages 55 years and up
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).
at UCSF UC Davis UCLA UC Irvine UCSD
-
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Sorry, not currently recruiting here
This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
at UC Irvine
-
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Sorry, not currently recruiting here
This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
at UCSD UCLA UCSF
Last updated: